Pages that link to "Q41926512"

The following pages link to Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. (Q41926512):

Displaying 26 items.

• Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions. (Q30385272) (← links)
• Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent (Q30434964) (← links)
• Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions (Q30474759) (← links)
• Nanomedicine strategies for molecular targets with MRI and optical imaging. (Q30481471) (← links)
• Characterization of mitral valve anterior leaflet perfusion patterns. (Q33825357) (← links)
• Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents (Q34058557) (← links)
• Quantitative cardiovascular magnetic resonance for molecular imaging (Q34330885) (← links)
• Nanoimaging in cardiovascular diseases: Current state of the art. (Q35640852) (← links)
• Multimodality and molecular imaging of matrix metalloproteinase activation in calcific aortic valve disease (Q35679982) (← links)
• From molecules to myofibers: multiscale imaging of the myocardium (Q36019181) (← links)
• Liquid perfluorocarbons as contrast agents for ultrasonography and (19)F-MRI. (Q37630410) (← links)
• Combining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis (Q37696318) (← links)
• Quantitative magnetic resonance fluorine imaging: today and tomorrow (Q37766558) (← links)
• Aortic Valve Disease: Preventable Or inevitable? (Q37818210) (← links)
• Pathophysiologic mechanisms of calcific aortic stenosis (Q37987807) (← links)
• Molecular Magnetic Resonance Imaging for the Detection of Vulnerable Plaques: Is It Possible?: Retracted (Q38081881) (← links)
• What can we learn about valvular heart disease from PET/CT? (Q38135890) (← links)
• Cell tracking using (19)F magnetic resonance imaging: technical aspects and challenges towards clinical applications. (Q38265406) (← links)
• Screening of CEST MR contrast agents. (Q38577489) (← links)
• Thyroid Hormone, Hormone Analogs, and Angiogenesis. (Q38693285) (← links)
• Bimodal perfluorocarbon nanoemulsions for nasopharyngeal carcinoma targeting (Q39178816) (← links)
• 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles (Q39262306) (← links)
• Molecular imaging of calcific aortic valve disease (Q47649340) (← links)
• Relaxometric studies of gadolinium-functionalized perfluorocarbon nanoparticles for MR imaging. (Q50623896) (← links)
• Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study (Q57183923) (← links)
• A Hyperfluorinated Hydrophilic Molecule for Aqueous F MRI Contrast Media (Q59809946) (← links)